a_unique_person
Director of Hatcheries and Conditioning
Yes, you don't just get a free trade agreement when you sign up with the States, you get the associated baggage like evergreen patents.
One more example of Big Companies contempt for 'free enterprise'.
http://www.theage.com.au/articles/2004/08/06/1091732084185.html?from=storylhs
Yep, a large company can indeginitely delay a generic drug maker from making a drug just by lodging spurious and speculative new 'patent' claims on it, this delay can be indefinitely.
Hardly the action of a 'free' enterprise system.
One more example of Big Companies contempt for 'free enterprise'.
http://www.theage.com.au/articles/2004/08/06/1091732084185.html?from=storylhs
Patents allow the company that developed a drug to market it free from competition, in return for making public its original data. It is a system that balances reward of innovation in research and development with the public benefit of dispersed knowledge.
Advertisement Advertisement
Drug patent evergreening is the single most important strategy that multinational pharmaceutical companies have been using since 1983 in the US (and since 1993 in Canada) to retain profits from "blockbuster" (high sales volume) drugs for as long as possible.
When the original patent over the active compound of a brand-name drug is due to expire, these drug companies often claim large numbers of complex and often highly speculative patents. Laws in the US and Canada require manufacturers to notify the original brand-name patent holders of their intention to market copies at the expiry of the original patent. The original patent holders can then threaten these potential generic competitors with breaching their now "evergreened" patents and seek a court order preventing their marketing approval.
The ultimate consequence could be elderly and poor Australians paying four times the present price for drugs.
The problem is a severe one in the US. In 2002, an extensive inquiry by the US Federal Trade Commission found that as many as 75 per cent of new drug applications by generic drug manufacturers were the subject of legal actions under patent laws by the original brand-name patent owner. These were driving up US drug costs by keeping the cheaper generic versions off the market.
In Canada, a similarly extensive investigation by the Competition Bureau revealed similar problems with drug patent evergreening. It found that the hundreds of legal actions involving evergreening claims were having a disastrous effect on drug prices.
.....
It requires that TGA drug marketing approval be "prevented" indefinitely (not for the 30-month and 24-month periods as in the US and Canada) whenever any type of patent (including a speculative evergreening patent) is merely "claimed".
Yep, a large company can indeginitely delay a generic drug maker from making a drug just by lodging spurious and speculative new 'patent' claims on it, this delay can be indefinitely.
Hardly the action of a 'free' enterprise system.